Government Relations & Regulatory
GOVERNMENT RELATIONS & REGULATORY
We help companies navigate the rules and regulations that govern their industries. Knowing how government works, we navigate opportunities that open doors for growth, innovation and profit.
Government regulations are complex. And every time the rules change, your company likely will face new challenges.
Nixon Peabody’s Government Relations & Regulatory practices offer the combined knowledge, experience and connections of more than 50 attorneys and professionals, many with backgrounds working for the agencies or legislative bodies governing our clients. Our team includes a former member of the U.S. Congress, a former U.S. Senator and attorneys who worked in various regulatory agencies, at both federal and state levels.
From our vantage point in Washington, DC, and in commercial centers across Europe and Asia, we help companies anticipate, navigate and comply with the myriad regulations that govern their industries.
Whether you need a voice in Congress or before a local administrative board, we advocate for legislative or policy changes that align with your business strategy.
Who we work with
Public and private organizations who want to stay ahead of the competition by anticipating government legislation, regulation and policy changes.
- FDA's Biggest New Policies of 2014: Midyear Report
Law360 | July 28, 2014
Washington, DC, Health Care and Life Sciences partner Areta Kupchyk is quoted in this forward-looking feature story on new rules and guidance from the U.S. Food and Drug Administration making waves for drug and device makers.
- Versar picks up J.M. Waller
The Deal | July 2, 2014
Client J.M. Waller Associates’ sale to Versar, Inc. is highlighted in this piece. The coverage notes J.M. Waller’s legal team led by securities practice group leader John Partigan and includes partners Brian Kopp and Christian McBurney; associate Pierce Han; and paralegal Alicia Rotella.
- Personalized Medicine Changes the Rules of the Play (Personoitu Laaketiede Muuttaa Pelisaantoja)
Mediuutiset (Finland) | March 21, 2014
In this Finnish health care publication, Boston Patents counsel Leena Karttunen Contarino provides commentary on how the FDA defines personalized medicine and about the FDA’s attempts to handle personalized medicine drugs and devices in an integrated process.